Early research (Phase 1)Study completedNCT01636622What this trial is testingStudy of Vemurafenib, Carboplatin, and PaclitaxelWho this might be right forAdvanced Cancers M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)UnknownNCT05102292What this trial is testingThe Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationWho this might be right forAnaplastic Thyroid CancerATC Shanghai Henlius Biotech 25
Early research (Phase 1)Study completedNCT01225536What this trial is testingDose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS MutationsWho this might be right forSolid Tumor ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 24
Early research (Phase 1)UnknownNCT05019534What this trial is testingTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal CancerWho this might be right forBRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody West China Hospital 12
Testing effectiveness (Phase 2)Study completedNCT05510895What this trial is testingNeoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal CancerWho this might be right forColorectal CancerColon CancerBRAF V600E+2 more AIO-Studien-gGmbH 2
Early research (Phase 1)Looking for participantsNCT06536400What this trial is testingPhase I Study of HSK42360 in Solid Tumors With BRAF V600 MutationWho this might be right forSolid Tumors Haisco Pharmaceutical Group Co., Ltd. 316
Not applicableActive Not RecruitingNCT07022457What this trial is testingUK ENcorafenib and BInimetinib Real-world Study in MelanomaWho this might be right forMetastatic Melanoma, BRAF V600 Mutation Positive Pierre Fabre Ltd 50
Early research (Phase 1)Study completedNCT01231594What this trial is testingA Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive TumorsWho this might be right forCancer Novartis Pharmaceuticals 214
Testing effectiveness (Phase 2)Looking for participantsNCT06763029What this trial is testingIrinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal CancerWho this might be right forColorectal Cancer Metastatic Fudan University 36
Testing effectiveness (Phase 2)Ended earlyNCT01942993What this trial is testingThe Effects of Treatment With Vemurafenib on the Immune System in Advanced MelanomaWho this might be right forMelanoma Philip Friedlander 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03839342What this trial is testingBinimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF MutationsWho this might be right forSolid Tumor University Health Network, Toronto 26
Early research (Phase 1)Study completedNCT01910181What this trial is testingVemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic MelanomaWho this might be right forMalignant Melanoma Hoffmann-La Roche 46
Testing effectiveness (Phase 2)Looking for participantsNCT07110246What this trial is testingDabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasWho this might be right forBRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more University of California, San Francisco 96
Early research (Phase 1)WithdrawnNCT04759846What this trial is testingHepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF MelanomaWho this might be right forBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more Pierre Fabre Medicament
Early research (Phase 1)Study completedNCT01596140What this trial is testingVemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerWho this might be right forAdvanced CancerSolid Tumor M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)Looking for participantsNCT05800340What this trial is testingNeoadjuvant Immunotherapy in Rare Mutations Localized NSCLCWho this might be right forNon-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more Guangdong Provincial People's Hospital 30
Not applicableEnrolling By InvitationNCT07122882What this trial is testingIntegrated Genomics in Oncogene-driven NSCLC With Acquired ResistanceWho this might be right forOncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more Chang Gung Memorial Hospital 40
Early research (Phase 1)Study completedNCT01954043What this trial is testingA Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsWho this might be right forCancer GlaxoSmithKline 23
Not applicableStudy completedNCT01804140What this trial is testingA Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)Who this might be right forMultiple Myeloma, Neoplasms Genentech, Inc. 662
Testing effectiveness (Phase 2)Study completedNCT02278133What this trial is testingStudy of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway MutationsWho this might be right forMetastatic Colorectal Cancer Array BioPharma 20